Form 4: Oric Pharmaceuticals CFO Sells Over 2,900 Shares Under Pre-Arranged Trading Plan

Oric Pharmaceuticals' Chief Financial Officer, Dominic Piscitelli, sold a total of 2,900 shares of common stock in early June 2025, pursuant to a Rule 10b5-1 trading plan established in December 2024.

Summary

• Dominic Piscitelli, Chief Financial Officer of Oric Pharmaceuticals, Inc. (ORIC), reported the sale of common stock.
• On June 6, 2025, Mr. Piscitelli sold 2,600 shares of common stock at a weighted average price of $10.0082 per share, with prices ranging from $10.00 to $10.04.
• On June 9, 2025, an additional 300 shares of common stock were sold at a price of $10.00 per share.
• Following these transactions, Mr. Piscitelli beneficially owns 103,864 shares of Oric Pharmaceuticals common stock.
• All reported sales were executed under a Rule 10b5-1 trading plan, which was adopted by Mr. Piscitelli on December 30, 2024.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, but mitigated by the fact that the sales were pre-planned under a 10b5-1 plan, indicating they were not based on immediate, undisclosed negative information.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, adopted on December 30, 2024, indicating that the transactions were pre-scheduled and not based on immediate, non-public information, which enhances transparency and reduces concerns about opportunistic insider trading.

Negatives

• The Chief Financial Officer's sale of shares, even if pre-planned, reduces his direct ownership stake in the company, which can sometimes be perceived negatively by investors as it may suggest a lack of confidence, although this is mitigated by the 10b5-1 plan.

Risks

• While the sales were pre-planned, a reduction in insider ownership could be interpreted by some market participants as a potential signal, which might contribute to negative sentiment or downward pressure on the stock price.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024.
• The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Industry Context

This document is a company-specific insider transaction report and does not provide broader industry trends or context. Insider sales are a routine disclosure requirement for publicly traded companies across all industries.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a neutral to slightly negative signal, potentially influencing their perception of management's confidence or future stock performance, although the 10b5-1 plan provides transparency.

Key Dates

Keywords

Oric Pharmaceuticals, ORIC, Form 4, Insider Trading, Dominic Piscitelli, CFO, Stock Sale, 10b5-1 Plan, Beneficial Ownership